Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06902558 · ClinicalTrials.gov registry record · Phase 2

A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2 study of Autosomal Dominant Polycystic Kidney Disease, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT06902558 is a Phase 2 study of Autosomal Dominant Polycystic Kidney Disease that is actively recruiting participants, run by AbbVie. The registered enrollment target is 240 participants, above the 135-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (78% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06902558, a Phase 2 study of Autosomal Dominant Polycystic Kidney Disease, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Around 240 adult participants with ADPKD will be enrolled at approximately 100 sites worldwide. Participants will receive IntraVenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks. Participants will be followed for up to 15 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions Studied

Autosomal Dominant Polycystic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG ABBV-CLS-628

Study Locations (20)

Florida

  • Horizon Research Group - Coral Gables /ID# 270857 - Coral Gables
  • South Florida Research Institute /ID# 270848 - Fort Lauderdale
  • Nature Coast Clinical Research - Inverness /ID# 270875 - Inverness
  • Mayo Clinic Hospital Jacksonville /ID# 271011 - Jacksonville
  • Panax Clinical Research /ID# 270851 - Miami
  • Infigo Clinical Research /ID# 270844 - Sanford

California

  • National Institute of Clinical Research - Garden Grove /ID# 271418 - Garden Grove
  • Valiance Clinical Research - Huntington Park /ID# 270634 - Huntington Park
  • Academic Medical Research Institute - Los Angeles /ID# 270502 - Los Angeles
  • UC Irvine Medical Center /ID# 270811 - Orange
  • University Of California, San Francisco /ID# 270326 - San Francisco

Idaho

  • CARE-Boise Kidney /ID# 270628 - Boise
  • CARE Institute - Idaho Falls /ID# 272005 - Idaho Falls

Massachusetts

  • Tufts Medical Center /ID# 270323 - Boston
  • Beth Israel Deaconess Medical Center /ID# 271408 - Boston

Connecticut

  • Yale University School of Medicine /ID# 270675 - New Haven

Georgia

  • Emory University School Of Medicine - Atlanta /ID# 271947 - Atlanta

Illinois

  • Northwestern University Feinberg School of Medicine /ID# 271409 - Chicago

Iowa

  • University of Iowa /ID# 270492 - Iowa City

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-06-09
Est. Completion 2029-08
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06902558

The ClinicalTrials.gov registry entry for NCT06902558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (78% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06902558 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Idaho.

Frequently Asked Questions

What is clinical trial NCT06902558 about?

NCT06902558 is a clinical study titled "A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)". Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants. ABBV-CLS...

What is the current status of trial NCT06902558?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-06-09. Estimated completion is 2029-08.

What conditions does trial NCT06902558 study?

This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.

What interventions are being tested in trial NCT06902558?

The interventions under investigation include: Placebo (DRUG), ABBV-CLS-628 (DRUG).

Who is sponsoring clinical trial NCT06902558?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06902558 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autosomal Dominant Polycystic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Autosomal Dominant Polycystic Kidney Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.